OEM and CDMO Models in Life Sciences Explained
By Giuseppina Sannino, PhD
Choosing an outsourcing partner starts with deciding what you need to retain control of and what you want someone else to provide.
Do you need an established reagent or instrument to incorporate into your offer? Or do you need a partner to develop a process and manufacture a product to agreed specifications?
OEM and CDMO arrangements can address these needs, but the labels do not tell you who owns the intellectual property, who carries regulatory responsibilities or how easily production can move elsewhere.
What the terms mean
OEM stands for original equipment manufacturer. In life-science supply arrangements, the term can describe a supplier providing components, reagents, instruments or finished products for another company to integrate into its offering or sell under its brand. OEM services may also include custom development.
Usage varies: “OEM” can refer to the supplier or to the company incorporating the supplied technology. Define the parties and activities explicitly.
A CDMO, or contract development and manufacturing organization, provides development and manufacturing capabilities under contract. An individual project may cover development, manufacturing or both.
Commercial supplier offerings illustrate the overlap: OEM programmes can include customization and development, while CDMOs can support several stages between development and commercial production. [1, 2]
How the arrangements differ
| Question | OEM supply arrangement | CDMO arrangement |
|---|---|---|
| What is being purchased? | A supplied product, component or platform, sometimes with customization | Defined development and manufacturing activities |
| Where does development begin? | May start from an existing supplier design or a custom specification | May start from an early concept, an established process or a technology transfer |
| Who owns the intellectual property? | Determined by the agreement | Determined by the agreement, including pre-existing technology and new work |
| What needs particular attention? | Integration, specifications, supply continuity and change notifications | Deliverables, development risk, process transfer, capacity and access to records |
Neither model guarantees faster development, lower costs or successful scale-up. Those outcomes depend on the technology, project maturity, partner capability and agreement.
Start with a defined scope
Consider two illustrative situations.
A diagnostic company needs an enzyme formulation for an assay it is developing. An OEM supplier may provide an established formulation, a customized version or support with development and commercial supply.
Another company has a promising assay but needs help transferring it into a reproducible production process. A development and manufacturing partner may support formulation, process development, testing, filling and packaging.
The important distinction is the work required. Ask what the partner will deliver, how acceptance will be assessed and what remains your responsibility.
Separate manufacturing work from regulatory responsibility
For EU IVDs, outsourcing production does not by itself transfer the legal manufacturer’s obligations.
Article 2(23) of the IVDR includes a company that has a device designed or manufactured and markets it under its own name or trademark. Article 10 sets out manufacturer obligations. [3]
Article 16 also addresses circumstances in which importers, distributors or other parties assume manufacturer obligations. Its own-name provision includes an exception where a distributor or importer has an agreement with the manufacturer, the manufacturer is identified on the label and remains responsible for the applicable requirements. [3]
The precise arrangement therefore matters. Identify the regulatory roles and ensure that labelling, documentation and contracts are consistent. A contract can allocate work, but it cannot override statutory responsibilities.
These device-specific rules should not automatically be applied to every research reagent or raw material.
Ask the questions that matter before signing
- Intellectual property: What does each party already own? Who owns new developments, and what rights are needed to use them?
- Quality: Which specifications, acceptance criteria, records and investigation procedures apply?
- Changes: Which changes require notification or approval, and how much notice is required?
- Supply: What capacity, lead times, minimum orders and continuity arrangements are available?
- Transfer and exit: Can production move elsewhere? Which records, materials, licences and technical assistance would be available?
- Commercial terms: How are development costs, failed work, price changes and termination handled?
Resolve these questions while both parties are defining the project, rather than after the product depends on the relationship.
Qualify the supplier for the actual work
Review the relevant site, capabilities, quality arrangements and experience with comparable processes.
ISO 13485 is a medical-device quality-management-system standard. Where relevant, examine a supplier’s certification scope and the activities and locations it covers. A certificate alone does not demonstrate that a particular product is approved or that the supplier can meet your project requirements. [4]
Make the qualification proportionate to the consequences of failure. A critical assay reagent and a replaceable packaging component may warrant different levels of scrutiny.
Frequently asked questions
Is an OEM the same as a white-label supplier?
Not necessarily. White-label arrangements generally involve selling an existing product under another brand. OEM arrangements can also involve components, integration and substantial customization. Define the scope rather than relying on the label.
Do these models apply to diagnostics and molecular tools?
Yes. They can involve reagents, assay components, instruments and manufacturing services. The applicable obligations depend on the product, intended use, market and each party’s role.
Does this article replace legal or regulatory advice?
No. It provides a commercial overview. Have the proposed arrangement reviewed against the actual product, jurisdictions and responsibilities involved.
Sources
- Thermo Fisher Scientific: Molecular Diagnostics Development, OEM and Commercial Supply
- Lonza: Contract development and manufacturing
- Regulation (EU) 2017/746, particularly Articles 2(23), 10 and 16
- ISO 13485:2016: Medical devices, quality management systems, requirements for regulatory purposes
Supplier pages illustrate commercial offerings; they are not independent endorsements or regulatory authorities.
Keep reading
Published 6 October 2026. Giuseppina Sannino, PhD.